H.C. Wainwright Thinks Adamis Pharma’s Stock is Going to Recover

By Austin Angelo

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP). The company’s shares closed yesterday at $2.75, close to its 52-week low of $2.20.

Kolbert commented:

“EpiPen as an Exchange NASDAQ Value (M) $65.4 Market Cap (M) $101 Shares Outstanding (M) 45.1 3 Interest (M) 3.55 Cash (M) $37.9 Total Debt (M) $2.3 Cash balances and share count are projected based on 3Q18 capital raise.”

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -4.1% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.

Adamis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 251.6% upside from current levels. In a report issued on August 10, Maxim Group also maintained a Buy rating on the stock with a $13 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $5.85 and a one-year low of $2.20. Currently, Adamis Pharma has an average volume of 852.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.